<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:51:07 -0700</creation_date>
  <update_date>2013-05-27 11:29:51 -0600</update_date>
  <accession>HMDBP00655</accession>
  <secondary_accessions>
    <accession>5927</accession>
    <accession>HMDBP07180</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>CGB-PDE</synonym>
    <synonym>cGMP-binding cGMP-specific phosphodiesterase</synonym>
  </synonyms>
  <gene_name>PDE5A</gene_name>
  <general_function>Involved in catalytic activity</general_function>
  <specific_function>Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP.
</specific_function>
  <pathways>
    <pathway>
      <name>3',5'-cyclic GMP degradation</name>
      <smpdb_id/>
      <kegg_map_id/>
    </pathway>
    <pathway>
      <name>Purine metabolism</name>
      <smpdb_id/>
      <kegg_map_id>map00230</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00608</accession>
      <name>Cobalt</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00547</accession>
      <name>Magnesium</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01333</accession>
      <name>Manganese</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00045</accession>
      <name>Adenosine monophosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00058</accession>
      <name>Cyclic AMP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01314</accession>
      <name>Cyclic GMP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01397</accession>
      <name>Guanosine monophosphate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB05039</accession>
      <name>Sildenafil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01889</accession>
      <name>Theophylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14944</accession>
      <name>Pentoxifylline</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14958</accession>
      <name>Tadalafil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15000</accession>
      <name>Vardenafil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15110</accession>
      <name>Dipyridamole</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00094</accession>
      <name>Citric acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15628</accession>
      <name>Udenafil</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydrolase activity, acting on ester bonds</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>phosphoric ester hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>phosphoric diester hydrolase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cyclic-nucleotide phosphodiesterase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>biological regulation</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of biological process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>regulation of cellular process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signal transduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>3',5'-cyclic-GMP phosphodiesterase activity</description>
      <go_id>GO:0047555</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>3',5'-cyclic-nucleotide phosphodiesterase activity</description>
      <go_id>GO:0004114</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>cGMP binding</description>
      <go_id>GO:0030553</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>metal ion binding</description>
      <go_id>GO:0046872</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>zinc ion binding</description>
      <go_id>GO:0008270</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>blood coagulation</description>
      <go_id>GO:0007596</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cGMP catabolic process</description>
      <go_id>GO:0046069</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of cardiac muscle contraction</description>
      <go_id>GO:0055118</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>negative regulation of T cell proliferation</description>
      <go_id>GO:0042130</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>nervous system development</description>
      <go_id>GO:0007399</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of apoptotic process</description>
      <go_id>GO:0043065</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of cardiac muscle hypertrophy</description>
      <go_id>GO:0010613</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of chronic inflammatory response</description>
      <go_id>GO:0002678</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of MAP kinase activity</description>
      <go_id>GO:0043406</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of oocyte development</description>
      <go_id>GO:0060282</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of vasoconstriction</description>
      <go_id>GO:0045907</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>regulation of the force of heart contraction</description>
      <go_id>GO:0002026</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>relaxation of cardiac muscle</description>
      <go_id>GO:0055119</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to hypoxia</description>
      <go_id>GO:0001666</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to lipopolysaccharide</description>
      <go_id>GO:0032496</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to testosterone stimulus</description>
      <go_id>GO:0033574</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>short-term memory</description>
      <go_id>GO:0007614</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>signal transduction</description>
      <go_id>GO:0007165</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>vasodilation</description>
      <go_id>GO:0042311</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasmic</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>4</chromosome_location>
    <locus>4q27</locus>
    <gene_sequence>&gt;2628 bp
ATGGAGCGGGCCGGCCCCAGCTTCGGGCAGCAGCGACAGCAGCAGCAGCCCCAGCAGCAG
AAGCAGCAGCAGAGGGATCAGGACTCGGTCGAAGCATGGCTGGACGATCACTGGGACTTT
ACCTTCTCATACTTTGTTAGAAAAGCCACCAGAGAAATGGTCAATGCATGGTTTGCTGAG
AGAGTTCACACCATCCCTGTGTGCAAGGAAGGTATCAGAGGCCACACCGAATCTTGCTCT
TGTCCCTTGCAGCAGAGTCCTCGTGCAGATAACAGTGTCCCTGGAACACCAACCAGGAAA
ATCTCTGCCTCTGAATTTGACCGGCCTCTTAGACCCATTGTTGTCAAGGATTCTGAGGGA
ACTGTGAGCTTCCTCTCTGACTCAGAAAAGAAGGAACAGATGCCTCTAACCCCTCCAAGG
TTTGATCATGATGAAGGGGACCAGTGCTCAAGACTCTTGGAATTAGTGAAGGATATTTCT
AGTCATTTGGATGTCACAGCCTTATGTCACAAAATTTTCTTGCATATCCATGGACTGATA
TCTGCTGACCGCTATTCCCTGTTCCTTGTCTGTGAAGACAGCTCCAATGACAAGTTTCTT
ATCAGCCGCCTCTTTGATGTTGCTGAAGGTTCAACACTGGAAGAAGTTTCAAATAACTGT
ATCCGCTTAGAATGGAACAAAGGCATTGTGGGACATGTGGCAGCGCTTGGTGAGCCCTTG
AACATCAAAGATGCATATGAGGATCCTCGGTTCAATGCAGAAGTTGACCAAATTACAGGC
TACAAGACACAAAGCATTCTTTGTATGCCAATTAAGAATCATAGGGAAGAGGTTGTTGGT
GTAGCCCAGGCCATCAACAAGAAATCAGGAAACGGTGGGACATTTACTGAAAAAGATGAA
AAGGACTTTGCTGCTTATTTGGCATTTTGTGGTATTGTTCTTCATAATGCTCAGCTCTAT
GAGACTTCACTGCTGGAGAACAAGAGAAATCAGGTGCTGCTTGACCTTGCTAGTTTAATT
TTTGAAGAACAACAATCATTAGAAGTAATTTTGAAGAAAATAGCTGCCACTATTATCTCT
TTCATGCAAGTGCAGAAATGCACCATTTTCATAGTGGATGAAGATTGCTCCGATTCTTTT
TCTAGTGTGTTTCACATGGAGTGTGAGGAATTAGAAAAATCATCTGATACATTAACAAGG
GAACATGATGCAAACAAAATCAATTACATGTATGCTCAGTATGTCAAAAATACTATGGAA
CCACTTAATATCCCAGATGTCAGTAAGGATAAAAGATTTCCCTGGACAACTGAAAATACA
GGAAATGTAAACCAGCAGTGCATTAGAAGTTTGCTTTGTACACCTATAAAAAATGGAAAG
AAGAATAAAGTTATAGGGGTTTGCCAACTTGTTAATAAGATGGAGGAGAATACTGGCAAG
GTTAAGCCTTTCAACCGAAATGACGAACAGTTTCTGGAAGCTTTTGTCATCTTTTGTGGC
TTGGGGATCCAGAACACGCAGATGTATGAAGCAGTGGAGAGAGCCATGGCCAAGCAAATG
GTCACATTGGAGGTTCTGTCGTATCATGCTTCAGCAGCAGAGGAAGAAACAAGAGAGCTA
CAGTCGTTAGCGGCTGCTGTGGTGCCATCTGCCCAGACCCTTAAAATTACTGACTTTAGC
TTCAGTGACTTTGAGCTGTCTGATCTGGAAACAGCACTGTGTACAATTCGGATGTTTACT
GACCTCAACCTTGTGCAGAACTTCCAGATGAAACATGAGGTTCTTTGCAGATGGATTTTA
AGTGTTAAGAAGAATTATCGGAAGAATGTTGCCTATCATAATTGGAGACATGCCTTTAAT
ACAGCTCAGTGCATGTTTGCTGCTCTAAAAGCAGGCAAAATTCAGAACAAGCTGACTGAC
CTGGAGATACTTGCATTGCTGATTGCTGCACTAAGCCACGATTTGGATCACCGTGGTGTG
AATAACTCTTACATACAGCGAAGTGAACATCCACTTGCCCAGCTTTACTGCCATTCAATC
ATGGAACACCATCATTTTGACCAGTGCCTGATGATTCTTAATAGTCCAGGCAATCAGATT
CTCAGTGGCCTCTCCATTGAAGAATATAAGACCACGTTGAAAATAATCAAGCAAGCTATT
TTAGCTACAGACCTAGCACTGTACATTAAGAGGCGAGGAGAATTTTTTGAACTTATAAGA
AAAAATCAATTCAATTTGGAAGATCCTCATCAAAAGGAGTTGTTTTTGGCAATGCTGATG
ACAGCTTGTGATCTTTCTGCAATTACAAAACCCTGGCCTATTCAACAACGGATAGCAGAA
CTTGTAGCAACTGAATTTTTTGATCAAGGAGACAGAGAGAGAAAAGAACTCAACATAGAA
CCCACTGATCTAATGAACAGGGAGAAGAAAAACAAAATCCCAAGTATGCAAGTTGGGTTC
ATAGATGCCATCTGCTTGCAACTGTATGAGGCCCTGACCCACGTGTCAGAGGACTGTTTC
CCTTTGCTAGATGGCTGCAGAAAGAACAGGCAGAAATGGCAGGCCCTTGCAGAACAGCAG
GAGAAGATGCTGATTAATGGGGAAAGCGGCCAGGCCAAGCGGAACTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>875</residue_number>
    <molecular_weight>99984.14</molecular_weight>
    <theoretical_pi>6.09</theoretical_pi>
    <pfams>
      <pfam>
        <name>GAF</name>
        <pfam_id>PF01590</pfam_id>
      </pfam>
      <pfam>
        <name>PDEase_I</name>
        <pfam_id>PF00233</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;cGMP-specific 3',5'-cyclic phosphodiesterase
MERAGPSFGQQRQQQQPQQQKQQQRDQDSVEAWLDDHWDFTFSYFVRKATREMVNAWFAE
RVHTIPVCKEGIRGHTESCSCPLQQSPRADNSVPGTPTRKISASEFDRPLRPIVVKDSEG
TVSFLSDSEKKEQMPLTPPRFDHDEGDQCSRLLELVKDISSHLDVTALCHKIFLHIHGLI
SADRYSLFLVCEDSSNDKFLISRLFDVAEGSTLEEVSNNCIRLEWNKGIVGHVAALGEPL
NIKDAYEDPRFNAEVDQITGYKTQSILCMPIKNHREEVVGVAQAINKKSGNGGTFTEKDE
KDFAAYLAFCGIVLHNAQLYETSLLENKRNQVLLDLASLIFEEQQSLEVILKKIAATIIS
FMQVQKCTIFIVDEDCSDSFSSVFHMECEELEKSSDTLTREHDANKINYMYAQYVKNTME
PLNIPDVSKDKRFPWTTENTGNVNQQCIRSLLCTPIKNGKKNKVIGVCQLVNKMEENTGK
VKPFNRNDEQFLEAFVIFCGLGIQNTQMYEAVERAMAKQMVTLEVLSYHASAAEEETREL
QSLAAAVVPSAQTLKITDFSFSDFELSDLETALCTIRMFTDLNLVQNFQMKHEVLCRWIL
SVKKNYRKNVAYHNWRHAFNTAQCMFAALKAGKIQNKLTDLEILALLIAALSHDLDHRGV
NNSYIQRSEHPLAQLYCHSIMEHHHFDQCLMILNSPGNQILSGLSIEEYKTTLKIIKQAI
LATDLALYIKRRGEFFELIRKNQFNLEDPHQKELFLAMLMTACDLSAITKPWPIQQRIAE
LVATEFFDQGDRERKELNIEPTDLMNREKKNKIPSMQVGFIDAICLQLYEALTHVSEDCF
PLLDGCRKNRQKWQALAEQQEKMLINGESGQAKRN</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>O76074</uniprot_id>
  <uniprot_name>PDE5A_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>1RKP</pdb_id>
    <pdb_id>1T9R</pdb_id>
    <pdb_id>1T9S</pdb_id>
    <pdb_id>1TBF</pdb_id>
    <pdb_id>1UDT</pdb_id>
    <pdb_id>1UDU</pdb_id>
    <pdb_id>1UHO</pdb_id>
    <pdb_id>1XOZ</pdb_id>
    <pdb_id>1XP0</pdb_id>
    <pdb_id>2CHM</pdb_id>
    <pdb_id>2H40</pdb_id>
    <pdb_id>2H42</pdb_id>
    <pdb_id>2H44</pdb_id>
    <pdb_id>2XSS</pdb_id>
    <pdb_id>3B2R</pdb_id>
    <pdb_id>3BJC</pdb_id>
    <pdb_id>3HC8</pdb_id>
    <pdb_id>3HDZ</pdb_id>
    <pdb_id>3JWQ</pdb_id>
    <pdb_id>3JWR</pdb_id>
    <pdb_id>3LFV</pdb_id>
    <pdb_id>3MF0</pdb_id>
    <pdb_id>3SHY</pdb_id>
    <pdb_id>3SHZ</pdb_id>
    <pdb_id>3SIE</pdb_id>
    <pdb_id>3TGE</pdb_id>
    <pdb_id>3TGG</pdb_id>
    <pdb_id>3TSE</pdb_id>
    <pdb_id>3TSF</pdb_id>
  </pdb_ids>
  <genbank_gene_id>AF043731</genbank_gene_id>
  <genecard_id>PDE5A</genecard_id>
  <geneatlas_id>PDE5A</geneatlas_id>
  <hgnc_id>HGNC:8784</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, Sonnenburg WK, Francis SH, Corbin JD, Beavo JA, Ferguson K: Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene. 1998 Aug 17;216(1):139-47.</reference_text>
      <pubmed_id>9714779</pubmed_id>
    </reference>
    <reference>
      <reference_text>Yanaka N, Kotera J, Ohtsuka A, Akatsuka H, Imai Y, Michibata H, Fujishige K, Kawai E, Takebayashi S, Okumura K, Omori K: Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. Eur J Biochem. 1998 Jul 15;255(2):391-9.</reference_text>
      <pubmed_id>9716380</pubmed_id>
    </reference>
    <reference>
      <reference_text>Stacey P, Rulten S, Dapling A, Phillips SC: Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun. 1998 Jun 18;247(2):249-54.</reference_text>
      <pubmed_id>9642111</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zhou L, Thompson WJ, Potter DE: Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1999 Jul;40(8):1745-52.</reference_text>
      <pubmed_id>10393044</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Eum SJ, Park SY, Lee JO, Lee TG, Ro S, Cho JM: Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 2003 Sep 4;425(6953):98-102.</reference_text>
      <pubmed_id>12955149</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Guanosine monophosphate</name>
        <accession>HMDB01397</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Guanosine monophosphate</name>
        <accession>HMDB01397</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Theophylline</name>
        <accession>HMDB01889</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Pentoxifylline</name>
        <accession>HMDB14944</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tadalafil</name>
        <accession>HMDB14958</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tadalafil</name>
        <accession>HMDB14958</accession>
      </metabolite>
      <reference>
        <reference_text>Curran M, Keating G: Tadalafil.  Drugs. 2003;63(20):2203-12; discussion 2213-4.</reference_text>
        <pubmed_id>14498756</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tadalafil</name>
        <accession>HMDB14958</accession>
      </metabolite>
      <reference>
        <reference_text>Eardley I, Cartledge J: Tadalafil (Cialis) for men with erectile dysfunction.  Int J Clin Pract. 2002 May;56(4):300-4.</reference_text>
        <pubmed_id>12074215</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tadalafil</name>
        <accession>HMDB14958</accession>
      </metabolite>
      <reference>
        <reference_text>Montorsi F, Salonia A, Deho' F, Cestari A, Guazzoni G, Rigatti P, Stief C: Pharmacological management of erectile dysfunction.  BJU Int. 2003 Mar;91(5):446-54.</reference_text>
        <pubmed_id>12603396</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tadalafil</name>
        <accession>HMDB14958</accession>
      </metabolite>
      <reference>
        <reference_text>Rotella DP: Tadalafil Lilly ICOS.  Curr Opin Investig Drugs. 2003 Jan;4(1):60-5.</reference_text>
        <pubmed_id>12625031</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tadalafil</name>
        <accession>HMDB14958</accession>
      </metabolite>
      <reference>
        <reference_text>Roumeguere T, Sternon J, Schulman CC: [Erectile dysfunction and phosphodiesterase type 5 inhibitors].  Rev Med Brux. 2003 Jun;24(3):169-75.</reference_text>
        <pubmed_id>12891884</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Tadalafil</name>
        <accession>HMDB14958</accession>
      </metabolite>
      <reference>
        <reference_text>Zoraghi R, Francis SH, Corbin JD: Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry. 2007 Nov 27;46(47):13554-63. Epub 2007 Nov 3.</reference_text>
        <pubmed_id>17979301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, Francis SH: A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol Pharmacol. 2006 Nov;70(5):1822-31. Epub 2006 Aug 22.</reference_text>
        <pubmed_id>16926278</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Carrier S: Pharmacology of phosphodiesterase 5 inhibitors.  Can J Urol. 2003 Feb;10 Suppl 1:12-6.</reference_text>
        <pubmed_id>12625845</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Kim NN, Huang YH, Goldstein I, Bischoff E, Traish AM: Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci. 2001 Sep 28;69(19):2249-56.</reference_text>
        <pubmed_id>11669467</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Saenz de Tejada I, Angulo J, Cuevas P, Fernandez A, Moncada I, Allona A, Lledo E, Korschen HG, Niewohner U, Haning H, Pages E, Bischoff E: The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001 Oct;13(5):282-90.</reference_text>
        <pubmed_id>11890515</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Scheen AJ: [Medication of the month. Vardenafil (Levitra)]  Rev Med Liege. 2003 Sep;58(9):576-9.</reference_text>
        <pubmed_id>14626653</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Eum SJ, Park SY, Lee JO, Lee TG, Ro S, Cho JM: Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature. 2003 Sep 4;425(6953):98-102.</reference_text>
        <pubmed_id>12955149</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Wang H, Ye M, Robinson H, Francis SH, Ke H: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol. 2008 Jan;73(1):104-10. Epub 2007 Oct 24.</reference_text>
        <pubmed_id>17959709</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Vardenafil</name>
        <accession>HMDB15000</accession>
      </metabolite>
      <reference>
        <reference_text>Zoraghi R, Francis SH, Corbin JD: Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors. Biochemistry. 2007 Nov 27;46(47):13554-63. Epub 2007 Nov 3.</reference_text>
        <pubmed_id>17979301</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipyridamole</name>
        <accession>HMDB15110</accession>
      </metabolite>
      <reference>
        <reference_text>Kulkarni SK, Patil CS: Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects. Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):789-99.</reference_text>
        <pubmed_id>15672122</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipyridamole</name>
        <accession>HMDB15110</accession>
      </metabolite>
      <reference>
        <reference_text>Santini F, Casali G, Franchi G, Auriemma S, Lusini M, Barozzi L, Favaro A, Messina A, Mazzucco A: Hemodynamic effects of inhaled nitric oxide and phosphodiesterase inhibitor (dipyridamole) on secondary pulmonary hypertension following heart valve surgery in adults. Int J Cardiol. 2005 Aug 18;103(2):156-63.</reference_text>
        <pubmed_id>16080974</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipyridamole</name>
        <accession>HMDB15110</accession>
      </metabolite>
      <reference>
        <reference_text>Kruuse C, Lassen LH, Iversen HK, Oestergaard S, Olesen J: Dipyridamole may induce migraine in patients with migraine without aura.  Cephalalgia. 2006 Aug;26(8):925-33.</reference_text>
        <pubmed_id>16886928</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipyridamole</name>
        <accession>HMDB15110</accession>
      </metabolite>
      <reference>
        <reference_text>Jackson EK, Ren J, Zacharia LC, Mi Z: Characterization of renal ecto-phosphodiesterase.  J Pharmacol Exp Ther. 2007 May;321(2):810-5. Epub 2007 Feb 16.</reference_text>
        <pubmed_id>17308037</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dipyridamole</name>
        <accession>HMDB15110</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Citric acid</name>
        <accession>HMDB00094</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Citric acid</name>
        <accession>HMDB00094</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Udenafil</name>
        <accession>HMDB15628</accession>
      </metabolite>
      <reference>
        <reference_text>Gur S, Sikka SC, Hellstrom WJ: Novel phosphodiesterase-5 (PDE5) inhibitors in the alleviation of erectile dysfunction due to diabetes and ageing-induced oxidative stress. Expert Opin Investig Drugs. 2008 Jun;17(6):855-64.</reference_text>
        <pubmed_id>18491987</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Udenafil</name>
        <accession>HMDB15628</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Udenafil</name>
        <accession>HMDB15628</accession>
      </metabolite>
      <reference>
        <reference_text>Ahn GJ, Chung HK, Lee CH, Kang KK, Ahn BO: Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis. Asian J Androl. 2009 Jul;11(4):435-42. Epub 2009 May 25.</reference_text>
        <pubmed_id>19465935</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Udenafil</name>
        <accession>HMDB15628</accession>
      </metabolite>
      <reference>
        <reference_text>Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, Park JK: Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int. 2011 Jun;107(12):1943-7. doi: 10.1111/j.1464-410X.2010.09759.x. Epub       2010 Nov 5.</reference_text>
        <pubmed_id>21054754</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Udenafil</name>
        <accession>HMDB15628</accession>
      </metabolite>
      <reference>
        <reference_text>Kouvelas D, Goulas A, Papazisis G, Sardeli C, Pourzitaki C: PDE5 inhibitors: in vitro and in vivo pharmacological profile.  Curr Pharm Des. 2009;15(30):3464-75.</reference_text>
        <pubmed_id>19860692</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
